• Ocugen Inc (NASDAQ: OCGN) has announced the presentation of new preclinical data evaluating the efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases.

• The data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting.

• OCU200 is a biologic product candidate in preclinical development for sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet Age-Related Macular Degeneration (Wet-AMD).

• OCU200 inhibited cell proliferation, cell invasion, and tube formation by endothelial cells.

• In the oxygen-induced retinopathy (OIR) mice model, OCU200 significantly reduced avascular areas at a low dose (68% reduction) and high dose (68% reduction). The observed difference in both doses was not much.

• Also, significantly reduced neovascular tufts (NVs) at a low dose (59% reduction, P < 0.05) and high dose (58% reduction, P < 0.05) compared to vehicle-treated eyes, was observed.

• Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eyelea (aflibercept) reduced NVs by 77%. OCU200 (10 ug) showed comparable activity to aflibercept (20 ug).

• Price Action: OCGN shares fell 12.6% at $9.54 during the market trading session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Regeneron Reports Mixed Bag On Q1 Earnings; Eylea Franchise Boosts Revenue

• India Gives Emergency Use Nod To Roche-Regeneron's COVID-19 Antibody Cocktail

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.